3018836-86-4
Chemical Structure
DPM-1003
- CAS No.: 3018836-86-4
- Formula:C35H57N3O3
- Molecular Weight:567.85
InChIKey: DSEPFENKRHJFCG-DSAGSSSKSA-N
SMILES: O[C@H]1[C@]2([H])[C@@](CC[C@]3([C@@]2([H])CC[C@]3([H])[C@H](C)CCC(OC)=O)C)([H])[C@@]4([C@@](CC(CC4)NCCCCNCC5=CN=CC=C5)([H])C1)C
Biological Activity: DPM-1003 is an allosteric PTP1B inhibitor that acts through the non-catalytic C-terminal disordered segment. DPM-1003 inhibits CXCL12-directed migration, CXCR4-dependent PI3Kγ/AKT/mTOR, CXCR4-mediated AKT, CXCL2-stimulated AKT/ERK, and PMA-induced Akt phosphorylation. In APP/PS1 mice, DPM-1003 improves recognition/spatial memory and reduces fibrillar/non-fibrillar plaques and soluble/insoluble Aβ42. DPM-1003 can be used in research on transfusion-related acute lung injury (TRALI), Rett syndrome, and Alzheimer's disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DPM-1003 | 99.89% | DPM-1003 is an allosteric PTP1B inhibitor that acts through the non-catalytic C-terminal disordered segment. DPM-1003 inhibits CXCL12-directed migration, CXCR4-dependent PI3Kγ/AKT/mTOR, CXCR4-mediated AKT, CXCL2-stimulated AKT/ERK, and PMA-induced Akt phosphorylation. In APP/PS1 mice, DPM-1003 improves recognition/spatial memory and reduces fibrillar/non-fibrillar plaques and soluble/insoluble Aβ42. DPM-1003 can be used in research on transfusion-related acute lung injury (TRALI), Rett syndrome, and Alzheimer's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Song D, et al. PTP1B inhibitors protect against acute lung injury and regulate CXCR4 signaling in neutrophils. JCI Insight. 2022 Jul 22;7(14):e158199. [Content Brief]
-
[2]. Christopher A. Bonham, et al. Inhibition of protein tyrosine phosphatase PTP1B function ameliorates
pathophysiological deficits in Rett Syndrome. bioRxiv, 4 June 2026. - [3]. Cen Y, et al. PTP1B inhibition promotes microglial phagocytosis in Alzheimer's disease models by enhancing SYK signaling. Proceedings of the National Academy of Sciences of the United States of America. 2026 Feb 10;123(6):e2521944123.
